Diffuse Large B-Cell Lymphoma in the Portal Vein
간문맥에서 생긴 미만성 거대 B세포 림프종

Hyun Ji Lim, MD1, Mi-Suk Park, MD2*, Yeo-Eun Kim, MD1

1Department of Radiology, Seoul Medical Center, Seoul, Korea
2Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Tumor thrombus in the portal vein without any liver parenchymal abnormality is extremely rare. In the liver, the primary tumor most frequently presenting with intravascular tumor thrombi is hepatocellular carcinoma and lymphoma is rarely considered. Even though thrombosis occurs quite often in lymphoma, cases of tumor thrombus are rare and cases of tumor thrombus in the portal vein are even rarer. Only four cases of lymphoma with portal vein tumor thrombus have been reported to date and all cases were the result of direct extensions of a dominant nodal or extra-nodal mass. To our knowledge, there has been no report on diffuse large B-cell lymphoma (DLBCL) presenting only within the lumen of the portal vein and not intravascular B-cell lymphoma. We present the first case of DLBCL presenting only within the lumen of the portal vein in an immunocompetent patient.

Index terms Lymphoma; B-Cell Lymphoma; Portal Vein

INTRODUCTION

Intravascular lymphoma is very rare (1). Lymphoma in the portal vein is extremely rare, and all reported cases were formed as a direct extension of nodal or extra-nodal masses (1). We report a case of diffuse large B-cell lymphoma (DLBCL) confined to a portal vein, without any enlarged lymph node or extra-nodal mass.

CASE REPORT

A 67-year-old woman was referred to our hospital due to increased levels of carbohydrate antigen 19-9 (patient level, 138.60 U/mL; normal range, 0–34 U/mL) noted during a regular medical checkup. The patient was asymptomatic but had underlying type 2 diabetes mellitus and hypertension. From the results of a blood panel, liver enzymes, such alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, total protein, albumin, bilirubin, and coagulation system parameters were all within normal...
Lymphoma in the Portal Vein

Lymphoma in the Portal Vein

limits. Laboratory data also revealed that the patient was immune to hepatitis B or C infection. On contrast-enhanced CT, a low-attenuated lesion was seen in the right main portal vein (Fig. 1A). The lesion showed lower attenuation than the normal hepatic parenchyma in the pre-contrast phase, and very subtle homogenous enhancement in the arterial and portal venous phase (PVP). The lesion showed subtle peripheral enhancement in the delay phase. There was no evidence of focal liver lesions, liver cirrhosis, or splenomegaly. There were no abnormally enlarged lymph nodes or mass lesions in the abdomen or pelvic cavity.

On MRI using a 3 Tesla imaging system (MAGNETOM Tim Trio; Siemens Healthcare, Erlangen, Germany), the lesion in the right portal vein showed low signal intensity on T1-weighted imaging relative to the liver, and moderate to high signal intensity on T2-weighted imaging relative to the liver, with diffusion restriction. Dynamic enhancement imaging with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) showed a very subtle homogenous enhancement on arterial, portal venous, transitional phase, and hepatobiliary phases (Fig. 1B). Moreover, in dynamic enhanced images, right lobe of liver shows perfusion disorder caused by portal vein thrombosis (PVT). The right lobe liver shows slightly hyperintense signal in the arterial phase, hyperintense signal with clear boundaries in portal phase, isointense signal in transitional, and hypointense signal with clear margin sparing the subcapsular area on hepatobiliary phase compared to other liver parenchyma.

In fluorine-18 fluorodeoxyglucose (18F-FDG) PET CT, the lesion showed an intense FDG uptake (Fig. 1C).

The patient underwent a right lobectomy. From the pathology, the lesion was confined to the right portal vein without any parenchymal lesion (Fig. 1D). It was diagnosed as DLBCL, non-germinal center B-cell-like type. In immunohistochemical staining, CD20 was positive in 100%, MUM1 in 80%, Bcl-2 and c-Myc in 30%, and Ki-67 in 90% of tumor cells. CD3, CD10, chromogranin A, synaptophysin, and CD56 were negative in tumor cells.

DISCUSSION

Lymphoma rarely manifests within a vessel from a lymphadenopathy or a primary extranodal mass (1). Lymphoma in the portal vein is extremely rare, since it usually does not progress via intraluminal vascular extension. Only a few cases of portal vein lymphoma were found in the literature (1). All cases with portal vein lymphoma were formed as direct extensions of a dominant nodal or extra-nodal mass6. to the best of our knowledge, this is the first case of DLBCL presenting within the lumen of a portal vein, in the absence of lymphadenopathy or extra-nodal mass in an immunocompetent patient.

PVT can be formed due to many reasons, not only in patients with cirrhosis and hepatic tumors but also in patients without liver disease (such as septic thrombophlebitis from gastrointestinal sources) (2). Tumor-related PVT can be classified as malignant or benign according to the tumor’s extension into the veins (3). Our case was an isolated thrombus in the portal vein without any hepatic parenchymal abnormality. Therefore, it was crucial to determine the cause and differentiate between the benign and malignant thrombus.

There are several radiologic criteria for a malignant thrombus. If the thrombus shows enhancement at dynamic contrast-enhanced CT during the arterial phase by at least 20 HU (4)
or shows high attenuation in the PVP of over 56.9 HU (3), it suggests a possible malignancy. Other criteria for malignant thrombi are as follows: 1) expansion of the involved vessel (vessel diameter ≥ 1.8 cm for the main portal vein, ≥ 1.6 cm for the right portal vein, and ≥ 1.8 cm for the left portal vein and unequivocal enlargement when compared with nonaffected same-order portal vein branches in the same lobe), 2) obvious continuity between the tumor tissue and thrombus, and 3) complete lipiodolization of the thrombus confirmed at follow-up CT after transarterial chemoembolization (4). A malignant thrombus can show $^{18}$F-FDG avidity (2).

Fig. 1. A 67-year-old woman with lymphoma in the right portal vein. A. Contrast-enhanced CT images obtained during the pre-contrast phase (a), arterial phase (b), PVP (c), and delayed phase (d). CT images show a hypoattenuated lesion in the right portal vein (arrow, a), with very subtle homogenous enhancement (arrow, b and c) in the arterial and PVP. The lesion is enhanced to a lesser degree than the liver parenchyma (arrow, b and c) in the arterial and PVP. In the delayed phase, the lesion shows subtle peripheral enhancement (arrow, d). In the coronal image (e), the lesion is clearly seen as a bulging hypoattenuated mass confined to the portal vein (main, right, and left branches, arrow). PVP = portal venous phases
In our case the portal vein thrombus shows subtle enhancement in the arterial and portal phases and a bulging appearance in CT images and high uptake in 18F-FDG PET CT, suggesting malignancy.

The hepatocellular carcinomas (HCCs) are the most common primary liver malignant tumors and frequently cause malignant PVT (2). Other primary tumors for the origin of PVT could be neuroendocrine carcinoma of the pancreas or colon cancer (2). Although rare, there is a case report describing HCC as manifesting only as PVT without a parenchymal mass (5).
In lymphoma, thrombosis occurs quite often, especially in non-Hodgkin’s lymphoma (NHL; the global incidence rate of thrombosis in lymphoma is 6.4% and 6.5% in NHL) (6). However, portal vein tumor thrombosis of lymphoma is extremely rare except in immunocompromised patients (6). Regarding the tumor thrombus, only four cases of patients with portal vein lymphoma have been reported and all cases were formed as direct extensions of a dominant nodal or extra-nodal mass (1). In some cases, when intravascular large B-cell lymphoma (IVLBCl) concomitantly involves larger vessel such as the portal vein, splenic vein and mesenteric veins it might be difficult to differentiate with our case radiologically. However in this case report, we exclude IVLBCl since our case does not qualify the definition of IVLBCl (7). IVLBCl is a rare and aggressive form of NHL, and is characterized by the almost exclusive proliferation of lymphoma cells within the lumen of small blood vessels (7). Since our case does not involve small blood vessels but only the portal vein (which is considered a large blood vessel), it is hard to be classified as IVLBCl.

In CT scans, hepatic lymphoma generally shows lower density than the normal hepatic parenchyma before contrast enhancement, and lower homogeneous contrast enhancement than the normal hepatic parenchyma after contrast enhancement (8). In MRI, most hepatic lymphomas show low signal or equivalent signal intensity on T1-weighted imaging, and moderate to high signal intensity on T2-weighted imaging (8). After contrast enhancement, lymphomas

Fig. 1. A 67-year-old woman with lymphoma in the right portal vein. 
C. 18F-FDG PET CT image (a) and 18F-FDG PET image show high uptake in the right portal vein (b). 
D. The cut surface of the resected specimen. The lymphoma is confined to the right portal vein without any other parenchymal lesion. 
18F-FDG = fluorine-18 fluorodeoxyglucose
Lymphoma in the Portal Vein

typically show low signal intensity in the arterial phase and homogeneous delayed enhancement in the PVP, with equivalent signal intensity in the transitional phase (8).

The differential diagnosis between HCC and primary hepatic lymphoma (PHL) is important. Both HCC and PHL may occur in patients with risk factors, such as cirrhosis and viral hepatitis, show mild signal hyper-intensity on T2-weighted images, and may demonstrate restricted diffusion (8). In general, radiologic findings of lymphadenopathy below the level of the renal veins, poor lesion enhancement in all contrast-enhanced phases, and vascular encasement without thrombosis favor a diagnosis of lymphoma (8), while arterial phase enhancement, delayed contrast material washed out with capsular enhancement, and vascular thrombosis is more common in HCC (8).

Another differential point is that PVT in HCC patients usually shows a heterogeneous appearance and disruption of the portal vein walls (9). In our case, however, the PVT shows mild, homogeneous enhancement compared to liver parenchyma without disruption of the portal vein wall. The enhancement pattern with preservation of the vascular structure could be a clue for lymphoma, even though it is extremely rare (8).

Hepatic lymphomas are avidly hypermetabolic in 18F-FDG PET due to hypercellularity, while most HCCs are not (8). Lesions > 1.5 cm and with FDG accumulation higher than hepatic and splenic FDG are considered positive for lymphoma (10).

Isolated tumor thrombus located only in the portal vein is a rare condition and arriving at a differential diagnosis through imaging can be difficult. However, the significance of treatment difference between lymphoma and other primary tumors underscore the importance of keeping lymphoma in the differential diagnosis of a tumor thrombosis in portal vein (1).

Author Contributions
Conceptualization, all authors; data curation, all authors; formal analysis, all authors; investigation, all authors; methodology, all authors; project administration, P.M.; resources, P.M.; supervision, P.M.; visualization, all authors; writing—original draft, all authors; and writing—review & editing, all authors.

Conflicts of Interest
The authors have no potential conflicts of interest to disclose.

REFERENCES
1. Chauhan A, Garg N, Menias CO, Devine CE, Bhosale PR, Balachandran A. Tumor thrombus as a rare presentation of lymphoma: a case series of 14 patients. AJR Am J Roentgenol 2015;204:W398-W404
2. Quencer KB, Friedman T, Sheth R, Oklu R. Tumor thrombus: incidence, imaging, prognosis and treatment. Cardiovasc Diagn Ther 2017;7: S165-S177
3. Canellas R, Mehrkhani F, Patino M, Kambadakone A, Sahani D. Characterization of portal vein thrombosis (neoplastic versus bland) on CT images using software-based texture analysis and thrombus density (Hounsfield units). AJR Am J Roentgenol 2016;207:W81-W87
4. Kim JH, Lee JM, Yoon JH, Lee DH, Lee KB, Han JK, et al. Portal vein thrombosis in patients with hepatocellular carcinoma: diagnostic accuracy of gadoxetic acid-enhanced MR imaging. Radiology 2016;279:773-783
5. Saito M, Seo Y, Yano Y, Uehara K, Hara S, Momose K, et al. Portal venous tumor growth-type of hepatocellular carcinoma without liver parenchyma tumor nodules: a case report. Ann Hepatol 2013;12:969-973
6. Caruso V, Di Castelnuovo A, Meschengieser S, Lazari MA, De Gaetano G, Storti S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood 2010;115:5322-5328
7. Yasuda H, Ando J, Matsumoto T, Ogura K, Ozaki Y, Aritaka N, et al. Intravascular large B cell lymphoma with
간문맥에서 생긴 미만성 거대 B세포 림프종

임현지1 · 박미숙2* · 김여은1

간문맥 종양혈전이 있으면서 간 실질에 이상 소견이 없는 것은 매우 드문 일이다. 간에서 종양혈전이 있는 경우 간세포암이 가장 발생률이 높으며 림프종은 감별진단으로 잘 생각되지 않는다. 림프종의 종양혈전이 간문맥을 침범한 것은 이제까지 총 네 가지 경우에서만 보고되어 있고, 모든 경우에서 종양이 혈관으로 직접 전파되거나 또는 그 외의 림프종을 시사하는 다른 병변들이 있었다. 혈관 내 대세포 림프종이 간문맥을 함께 침범한 경우, 본 케이스와 영상학적으로 비슷하게 보일 수 있으나 본 증례 보고는 혈관 내 대세포 림프종이 아니므로 제외하여 생각하였다. 미만성 거대 B세포 림프종이 간문맥에서만 발견된 무증상의 면역력이 정상인 67세 여자 환자에 대한 증례를 소개한다. 이전에 발표된 증례에서 이와 비슷한 경우는 보고된 바가 없다.

1서울의료원 영상의학과, 2연세대학교 의과대학 세브란스병원 영상의학과

https://doi.org/10.3348/jksr.2020.81.3.707